[KIP1] (p27) is a cyclin dependent kinase inhibitor, involved in the negative regulation of G 1 progression in response to a number of anti-proliferative signals. In this study we show, in growing mouse hybridoma (7TD1) and human myeloma (U266) cell lines, that p27 is highly expressed but slightly upregulated when cells are arrested, regardless to the phases of the cell cycle. In contrast, the speci®c blockade of these cells in early G 1 phase reveals the induction of a protein of 23 kDa (p23) speci®cally recognized by polyclonal anti-p27 antibodies raised against the NH2 terminal part of p27 but not by anti-p21 [CIP1] antibodies. Experiments using caspase inhibitors strongly suggest that p23 results from the proteolysis of p27 by a`caspase-3-like' protease. This cleavage leads to the cytosolic sequestration of p23 but does not alter its binding properties to CDK2 and CDK4 kinases. Indeed, p23 associated in vivo with high molecular weight complexes and coprecipitated with CDK2 and CDK4. We demonstrate by transfection experiments in SaOS-2 cells that p23 induces a G 1 phase growth arrest by inhibition of cyclin/CDK2 activity. In summary we describe here a caspase-cleaved form of p27, induced in absence of detectable apoptosis and likely involved in cell cycle regulation.
Introduction
Cell cycle involves the assembly and activation of speci®c cyclin/cyclin-dependent kinase (CDK) complexes which regulate a temporally ordered series of checkpoints (Hunter and Pines, 1994; Sherr, 1994) . Dtype cyclins (D1, D2 and D3) are synthesized in early G 1 and behave as positive regulators of CDK4 and CDK6 kinases which elicit phosphorylation of the retinoblastoma protein pRb (Dowdy et al., 1993; Kato et al., 1993; Matsushime et al., 1994; Meyerson and Harlow, 1994) . Cyclin E/CDK2 complexes appear later in G 1 phase and probably regulate the G 1 /S transition (Dulic et al., 1992; Knoblich et al., 1994; Ko et al., 1992; Resnitszky et al., 1994) . The cyclin/CDK complexes can also be negatively modulated by two major classes of CDKs inhibitors (CKI). The p21 family of inhibitors comprises three distinct gene products p21 CIP1/WAF1/SDI1 (p21), p27 [KIP1] (p27) and p57 [KIP2] (p57), which bind and inhibit all the G 1 cyclin/CDK complexes and to a lesser extent cyclin B/CDC2 complexes (reviewed in Sherr, 1994 , bind speci®cally to CDK4 and CDK6 and thus prevent the association of cyclin D to CDKs. At variance with p21 and p27 which exhibit a higher anity for the cyclin/CDK complexes than for the monomeric CDK subunit, the INK4s inhibitors interact directly with the CDK alone (Hall et al., 1995; Sherr and Roberts, 1995) .
p27 plays a critical role in the negative control of cell growth. It is generally up-regulated in cells arrested either by cell contact, serum deprivation or after incubation with transforming growth factor-b (TGF-b) Polyak et al., 1994a; Slingerland et al., 1994) . In contrast, p27 usually declines in the presence of mitogenic agents like platelet-derived growth factor, macrophage stimulating factor or interleukin-2 (Agrawal et al., 1996; Kato et al., 1994; Nourse et al., 1994) . Nevertheless, recent data obtained with p27 nullizygote mice have shown that cell cycle arrest induced by TGF-b, rapamycin or contact inhibition remains unaected (Nakayama et al., 1996) , suggesting that p27 is not the only CKI involved in cell growth arrest under these conditions.
We have shown in two interleukin-6 dependent cell lines, 7TD1 and U266, that growth arrest in early G 1 phase is associated with the speci®c expression of a 23 kDa protein (p23). This protein results from the proteolytic cleavage of p27 by à caspase-3-like' proteinase, in the absence of detectable apoptosis. The ectopic expression of this 23 kDa truncated form of p27 in SaOS-2 cells results in the blockade of cell growth in early G 1 demonstrating that p23 plays an active role in cell cycle regulation through its interaction with cyclin/ CDK complexes. blocked in dierent phases of the cell cycle. For this purpose, cells were incubated for 24 h in dierent conditions of growth arrest (see Materials and methods), then harvested and their cell cycle was analysed by¯ow cytometry. As reported previously in other cell systems (Liu et al., 1994; Lucas et al., 1992; Ponzio et al., 1998; Rezzonico et al., 1995; Takase et al., 1992; Teroaka et al., 1996) , 7TD1 cells were blocked in early G 1 phase by IL-6 depletion or treatment with DMSO and 8Br-cAMP, in late G 1 phase by aphidicolin and in G 2 /M phase by nocodazole treatment (Table 1) . Cells treated in these conditions were then lysed and protein extracts analysed by Western blot using a polyclonal antibody raised against the amino acids 1 ± 90 of p27 (p27(N90)). As shown in Figure 1, Table 1 , clearly indicated that p23 was only induced when cells were blocked in early G 1 phase.
Time course of p27 and p23 expression under DMSO treatment and after DMSO withdrawal
In these experiments we have used DMSO which proved to be the most ecient eector for blocking 7TD1 and U266 cells in early G 1 phase. As shown in Figure 2a , p27 was constitutively expressed at high levels in growing cells and was increased twice after 12 h of exposure to DMSO. At variance, p23 was undetectable in growing 7TD1 cells and during the ®rst 12 h of DMSO addition, but was strongly induced after 12 h and remained stable for at least 12 h in the presence of DMSO. As shown in Figure 2b , p23 also appeared in myeloma cells U266 treated for 24 h with DMSO.
The regulation of p23 and p27 was further studied after DMSO withdrawal. 7TD1 cells treated with 1% DMSO for 24 h were washed and resuspended in fresh medium in the presence or in the absence of IL-6. Results presented in Figure 2c show that p23 expression rapidly decreased after DMSO removal and became undetectable after 4 h regardless of the Figure 1 Detection of p27 and p23 in lysates of 7TD1 cells blocked in dierent phases of the cell cycle. 7TD1 cells were grown in presence (a lane 1 and b lane 6) or in absence of IL-6 (a lane 3); or cultured as described in Materials and methods, respectively with IL-6 plus DMSO (a lane 2), IL-6 plus 8Br-cAMP (b lane 7), IL-6 plus aphidicolin (a lane 4), or IL-6 plus nocodazole (a lane 5). p27 and p23 expressions were then analysed in total cellular extracts by Western blotting using the polyclonal p27(N90) antibody. Immunoblot were exposed for respectively 1 min (a) and 10 min (b) The IL-6 condition refers to cells grown in presence of IL-6 (100 U/ml). The other columns correspond to data obtained for cells deprived of IL-6 for 24 h, or treated with IL-6 plus DMSO (1.5%), IL-6 plus 8 Br-cAMP (500 mM), IL-6 plus aphidicolin (1 mg/ml) or IL-6 plus nocodazole (75 ng/ml) as described in Materials and methods addition of IL-6 in the culture medium. In the presence of IL-6, p23 remained undetectable for at least 24 h but in contrast, in the absence of IL-6, p23 reappeared at a high level after 24 h (Figure 2c ). This behaviour contrasts with that of p27 that slightly decreased after DMSO withdrawal but remained highly expressed in the presence or in the absence of IL-6. Cell cycle analysis showed that when DMSO was removed in the presence of IL-6, 7TD1 cells resumed their progression through the cycle with 98 and 67% of cells reaching the S phase after respectively 12 and 24 h ( Table 2) . As expected, after DMSO withdrawal and in the absence of IL-6, 72% of the cells entered in S phase after 12 h but only 28% after 24 h, indicating that in this condition the cells completed their cycle but failed to resume a new division cycle. This result was in accord to the well established growth dependency of 7TD1 cells for IL-6 (Hultner et al., 1989) . Taking together, these data highly suggest that the expression of p23 observed 24 h after DMSO withdrawal in the absence of IL-6, likely corresponds to a second G 1 arrest due to the lack of IL-6-mediated progression signals.
p23 is dierent from p21
Since our polyclonal anti-p27 antibody (p27(N90)) was raised against the NH2 terminal domain of p27, which is 44% homologous to p21 CIP1 (Polyak et al., 1994b) , we addressed the question whether p23 could correspond to p21. Using an anti-p21 antibody speci®c for mouse p21 we demonstrated in 7TD1 cells that p23 migrated with a higher apparent molecular weight than the murine p21 and that the expression pattern of these two proteins were totally dierent ( Figure 3a) . Indeed, as shown in lane 4, p21 was strongly expressed when 7TD1 cells were treated with aphidicolin while p23 was undetectable (Figure 1 , lane 4). In contrast, p21 was absent in cells blocked in early G 1 by IL-6 depletion (lane 3) or DMSO (lane 2) where p23 was maximally expressed (Figure 1 ). p23 is recognized by antibodies directed against the N-terminal but not the C-terminal part of p27
The expression of p27 and p23 in 7TD1 cells blocked in G 1 phase by DMSO were analysed by Western blotting using either our p27(N90) antibody or other polyclonal antibodies directed against the amino (p27(N20)) or the carboxy terminal (p27(C19)) part of p27. The results presented in Figure 3b indicated that both p27(N20) and p27(N90) but not p27(C19) antibodies were able to detect p23 protein, suggesting that p27 and p23 present structural homologies in their N-terminal sequence but dier in their carboxy terminal region.
p23 is exclusively located in the cytosol
Since the C-terminal part of p27 contains the nuclear localization site of the molecule we have examined the subcellular location of p27 and p23 in cells treated for 12 h with DMSO. Nuclear and cytosolic extracts were prepared (Rezzonico et al., 1995) and the expression of these two proteins was analysed by Western blot using the p27(N90) antibody. Results shown in Figure 4 clearly indicate that p23 was only present in the cytosol of 7TD1 cells, whereas p27 was recovered both in nuclear and cytosolic extracts. These data suggest that the cleavage of the C-terminal moiety lead to the loss of the nuclear localization site of p27 and consequently to the sequestration of p23 in the cytosolic compartment.
p23 likely results from the proteolysis of p27 by a CPP32-like protease
We sought to determine whether p23 could be generated by p27 cleavage. For this purpose we have The DMSO condition refers to cells blocked by DMSO treatment (1%) for 24 h. Cells were then washed and cultured in fresh medium in the absence or in the presence of IL-6 (100 U/ml) for the indicated times Whole cellular extracts were analysed using a speci®c polyclonal antibody directed against mouse p21. (b) p23 is not recognized by an antipeptide raised against the C-terminal part of p27. 7TD1 cells cultured in the absence (7) or in the presence (+) of DMSO for 24 h were analysed by Western blotting using either anti-p27(N90), anti-p27(C19) or antip27(N20) rabbit polyclonal antibodies tested the eect of dierent protease inhibitors on the induction of p23 by DMSO, in 7TD1 and U266 cells. When the two caspase-3 (CPP32) inhibitors, i.e. acetyl-Asp-Glu-Val-Asp-aldehyde (Ac-DEVD-CHO) and carbobenzoxy-Val-Ala-Asp-¯uoromethyl ketone (z-VAD-fmk) (Enari et al., 1996) were incubated with U266 cells, they blocked the DMSO-mediated expression of p23 ( Figure 5a , left panel) indicating that p23 likely resulted from the cleavage of p27 by a member of the caspase family. In 7TD1 cells, z-VAD-fmk also totally inhibited the induction of p23 induced by IL-6 deprivation ( Figure 5a , right panel).
The inhibition of p23 expression by caspase inhibitors prompted us to assess the eect of DMSO on the cleavage of poly(ADP-ribose) polymerase (PARP), one major substrate of CPP32 (Lazebnik et al., 1994) . As shown in Figure 5b , DMSO strongly increased PARP proteolysis (more than 80% of cleavage after 24 h of DMSO) both in 7TD1 (right panel) and in U266 cells (left panel), and this eect was inhibited by z-VAD-fmk and Ac-DEVD-CHO. However, in this condition (Figure 5c ), DMSO did not induce the proteolytic activation of CPP32 that remained under its proenzymatic form of 32 kDa (Nicholson et al., 1995; Tewari et al., 1995) . This data suggests that the caspase-3 itself was not involved in the cleavage of PARP but are indicative that à caspase-3-like' protease, dierent from CPP32, could participate to this proteolysis (see review of Cohen, 1997) .
DMSO does not induce apoptosis in 7TD1 cells
Since DMSO stimulated the cleavage of PARP in 7TD1 cells, the question raised whether this drug exerted an apoptotic eect in these two cell types. Apoptosis was assayed by measuring phosphatidyl serine (PS)¯ipping and disruption of the mitochondrial transmembrane potential (Castedo et al., 1996) . Results presented in Table 3 indicate that 24 h after the addition of DMSO, 0.7% of 7TD1 cells were apoptotic compared to the positive control obtained with anisomycin (10 mg/ml), which induced 60% of apoptosis in 7TD1 cells. Under similar conditions we observed that the percentage of the apoptotic population of U266 cells raised from 3.9 to 15% after 24 h of DMSO. However this percentage did not further increase over 72 h, and the number of living cells remained constant. Altogether these data suggested that in U266 cells DMSO was overall an antiproliferative agent, despite displaying a slight apoptotic eect.
p23 binds to CDK-containing complexes in 7TD1 cells blocked in G 1 phase
To gain information about the functional role of p23 in 7TD1 cells, we have examined whether p23 could associate to cyclin/CDK complexes. Total cellular extracts prepared from 7TD1 cells blocked in G 1 phase for 24 h with DMSO were fractionated by gel ®ltration chromatography on AcA 44. As shown in Figure 6a , p23, like p27, eluted mostly in fractions corresponding to proteins with M r 468 kDa suggesting that p23 was part of high molecular complexes. As shown in panels (b) and (c), CDK2 and CDK4 co-eluted with p23, suggesting its association to cyclin/CDK2, CDK4 complexes. This hypothesis was con®rmed by immunoprecipitation experiments showing that p23 was present in anti-CDK2 and anti-CDK4 immunoprecipitates obtained from lysates of cells treated with DMSO ( Figure 6d ). Cells (0.3610 6 ml) incubated for 24 h in the presence or in the absence of 1.5% DMSO or for 4 h with 10 mg/ml anisomycin were harvested and apoptosis was estimated as described in Materials and methods
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The ectopic expression of p23 in SaOS-2 arrests the cells in G 1 phase
The 7TD1 and U266 cell lines were ecient models to reveal the presence of p23 and to study its regulation within the cell cycle. However these cells express constitutive levels of p27 and therefore do not allow the approach of speci®c biological function of p23. Based upon the results obtained with the caspase inhibitors ( Figure 5) , and given the presence of a 136 DXXD 139 consensus caspase site in p27 sequence (Levkau et al., 1998; Polyak et al., 1994b; Talanian et al., 1997) , we have constructed a mammalian expression vector containing the cDNA sequence of the ®rst 408 base pairs of human p27, coding for the 23 kDa fragment comprised between Met 1 and Asp 139 (Figure 7  panel a) . This construction was used to express p23 into the osteosarcoma cell line SaOS-2 that does not exhibit endogenously p27 (Toyoshima and Hunter, 1994) . Western blot experiments (Figure 7b ) revealed that p27 and p23 were highly expressed in SaOS-2 cells after transfection with their respective cDNAs, compared to the void plasmid. Using the green uorescent protein (GFP) as reporter gene, we have estimated that about 15% of the cells were transfected in our conditions (data not shown). The subcellular localization of p23 and p27 in SaOS-2 was analysed by immunocytochemistry using anti-p27 (N20) antibodies (Figure 8 ). In cells transfected with p27 cDNA (pCDNA/p27) a strong labelling was visualized in the nucleus, whereas in cells expressing p23 (pCDNA/p23) the¯uorescence was randomly distributed in the cytosol due to the absence of nuclear localization signal.
Our objective was to determine the role of p23 in the cell cycle regulation. To this aim, the cDNAs of p23, p27 or a control plasmid were co-transfected with the cDNA coding for CD4, a surface protein absent in SaOS-2 cells. This procedure allowed the¯ow cytometric analysis of CD4 transfected population after immuno¯uorescent labelling. After 48 h, the DNA content of CD4 + cells was analysed by FACS. Results are shown in Figure 9 panel a. In control cells transfected with vector alone, 50% of the CD4 + cells were in G 1 . In contrast, 79% of CD4 + cells cotransfected with p23 expression vector and 83% of CD4 + cells co-transfected with p27 were in G 1 , with fewer cells in S and G 2 /M. These results clearly demonstrate that p23, like p27, arrested cells in G 1 .
The CD4 + cells were also analysed for apoptosis by double labelling using annexin-5 and a mitochondrial potential probe (Castedo et al., 1996) . Data shown in Figure 9b demonstrate that p23 or p27 failed to induce programmed cell death (0% in the lower right quadran).
In order to investigate the mechanism underlying the inhibitory eect of p23 on the cell cycle, we have analysed its association to cyclin/CDK complexes and its eect on CDK2 activity. Lysates from cells transfected with the cDNAs coding for p27 or p23 were immunoprecipitated with anti-CDK2 or anti-CDK4 antibodies, and immunopellets were analysed by Western blotting using anti-p27 (N90) antibody. The results shown in Figure 7c demonstrated that p23 and p27 eciently associate with cyclin/CDK2 and CDK4 complexes. These results suggest that p23 expressed ectopically in SaOS-2 cells, exhibited identical binding properties to those of p23 induced in vivo, in 7TD1 cells, after DMSO treatment. We have next veri®ed whether p23 was able to inhibit cyclin/ CDK2 activity. For in vitro experiments, p23 and p27 prepared from transfected SaOS-2 cells were incubated Western blot analysis of the levels of p27 and p23 in SaOS-2 cells transfected with a control vector (pCDNA3) and the pCDNA3 vector containing the cDNAs coding for p23 (pCDNA/p23) or p27 (pCDNA/p27). (c) Association of p27 and p23 with CDK2 and CDK4. Cyclin/ CDK2 (IP aCDK2) and cyclin/CDK4 (IP aCDK4) were immunoprecipitated from lysates of SaOS-2 cells transfected as above and the levels of p27 and p23 associated with each cyclin/ CDK complexes were evaluated by immunoblotting using antip27 (N90) antibody. These experiments were carried out four times. The presented experiment is a typical one with CDK2 immunoprecipitated from growing 7TD1 cells. CDK2 activity was then assayed using Histone H1 as substrate. As shown in Figure 10 , p23, like p27, inhibited the activity of cyclin/CDK2 in a dose dependent manner. The comparison of the dose responses of these two inhibitors showed that p23 inhibited CDK2 activity with a much higher eciency than p27. Indeed, the half-maximum inhibitory eect of p23 was ®ve to ten times lower than that of p27. To check the inhibitory eect of p23 in vivo, we have measured the activity of CDK2 in p23 and p27 positive cells. To this aim the cDNAs of p23, p27 or a control plasmid were co-transfected with the cDNA coding for CD4. After 48 h the CD4 + /control, CD4 + /p27 + and CD4 + /p23 + cells were puri®ed using an anti-CD4 antibody coupled to magnetic beads. The positive cells were lysed in RIPA buer and cyclin/CDK2 activity was measured after immunoprecipitation with anti-CDK2 antibodies. The results (Figure 10, inset) clearly indicated that the activity of cyclin/CDK2 complexes was abrogated in p23 + as well as in p27 + cells compared to control cells. Collectively these data suggested that p23 behaves as a true inhibitor of CDK2 activity not only in vitro but also in intact cells.
Discussion
This study was initially designed to explore the regulation of p27 during the cell cycle, in the IL-6-dependent murine B hybridoma cell line 7TD1 and in the human myeloma cell line U266. We have demonstrated that p27 was highly expressed in growing cells but was only slightly increased in arrested cells. Interestingly, besides p27, we have found that an anti-p27 antibody (p27(N90)) that we have raised against the ®rst 90 amino acids of p27, recognized another protein migrating with a molecular weight of 23 kDa (p23). Experiments using speci®c anti-p21 antibodies indicated that p23 was distinct from p21 or from any of the recently described p21- Figure 8 Subcellular localization of p27 and p23 in transfected SaOS-2 cells. SaOS-2 cells were transfected with a control vector (pCDNA3) or the plasmids expressing either p27 (pCDNA/p27) or p23 (pCDNA/p23). After 36 h the cells were ®xed and stained with the polyclonal anti-p27 (N90) antibody followed by a FITC-coupled anti-rabbit antibody and analysed by¯uorescent microscopy Figure 9 Eect of ectopic expressions of p23 and p27 on the cell cycle and apoptosis of SaOS-2 cells. Exponentially growing SaOS-2 cells were co-transfected with either pCDNA (control vector), pCDNA/p27 or pCDNA/23 and a pRc/CMV/CD4 vector. The cells were then labelled using a FITC conjugated anti-CD4 antibody, and cell cycle (a) and apoptosis (b) of CD4 + cells were analysed by¯ow cytometry using a FACScan as described in Materials and methods. The presented data are from a typical experiment chosen among two Figure 10 Eect of p27 and p23 on CDK2 activity in vitro and in intact cells. Lysates from SaOS-2 cells transfected with pCDNA/p27 or pCDNA/p23 were solubilized in RIPA buer, boiled for 5 min at 1008C and centrifuged at 15 000 r.p.m. for 15 min. Increasing volumes of each supernatant, containing identical amounts of p27 (&) or p23 (&), were then incubated with cyclin/CDK2 immunoprecipitated from lysates of 7TD1 cells and CDK2 activity was measured using Histone H1 as substrate. Inset: SaOS-2 cells, co-transfected with pCDNA3, pCDNA/p27 or pCDNA/p23 and a pRc/CMV vector containing human CD4 cDNA were puri®ed using an anti-CD4 antibody coupled to magnetic beads. The CD4 + cells were solubilized and CDK2 activity was measured using Histone H1 as substrate after immunoprecipitation with anti-CDK2 antibodies (IP aCDK2). Data presented in the ®gure were from a typical experiment chosen among respectively three (main graph) and two (inset) distinct experiments related proteins (Mazars and Jat, 1997; Tchou et al., 1996) . Unlike p27, p23 was undetectable in growing cells but appeared only in cells blocked in early G 1 . In contrast, p23 was not visible in cells blocked at the G 1 / S transition (aphidicolin) or in the G 2 /M phase (nocodazole).
Experiments designed to de®ne the molecular origin of p23 indicate that this molecule is unlikely a new Cip/Kip family member. Indeed, we never detected any p27-related mRNA in DMSO treated 7TD1 cells, either by Northern blot analysis in dierent stringency conditions or by RACE PCR using several pairs of primers (data not shown). In contrast, experiments carried out in vivo with permeant caspase inhibitors indicate that p23 probably results from the proteolytic cleavage of the carboxy terminal part of p27 by a CPP32-like caspase, activated in condition of growth arrest, but in absence of detectable apoptosis. This hypothesis is supported by the fact that a putative caspase-3 consensus cleavage sequence exists within p27 sequence (Asp Several lines of evidence indicate that p23 could actively participate in the control of cell cycle in 7TD1 cells under DMSO. Indeed, its induction strikingly parallels the rate of cell accumulation in G 1 phase. Elsewhere, p23 is rapidly and totally down-regulated as soon as the cells enter in S phase following drug withdrawal. As p23 down-regulation correlates with an increase of the phosphorylation of pRb (not shown), which is the major substrate for CDK4/2, we hypothesized that p23 might participate to the regulation of CDK4/2 activities. This was con®rmed by gel ®ltration and immunoprecipitation experiments demonstrating that p23 co-eluted and co-immunoprecipitated with CDK2 and CDK4 and therefore could modulate their kinase activity. Nevertheless, because of the high levels of p27 [KIP1] constitutively present in 7TD1 and U266 cells, it was not possible to further investigate the biological function of p23 in these cellular systems. To approach this question our strategy was to carry out transfection experiments in the SaOS-2 osteosarcoma cell line that does not express endogenous p27 in growing conditions. Based upon the results obtained with the caspase inhibitors, we have subcloned the cDNA sequence coding for the p23 fragment of p27 (amino acids 1 ± 136) into a mammalian expression vector and transfected it into SaOS-2 cells.
The analysis of the cell cycle of SaOS-2 cells transfected with p27 or p23 clearly indicates that overexpression of p23 led to the accumulation of cells in G 1 phase (79% with p23 versus 50% with a control vector) and strongly supports the notion that p23 induced in 7TD1 cells under DMSO could participate actively to the G 1 block. Nonetheless, transfection of p23 did not induce apoptosis in SaOS-2 cells, which is also consistent with the results obtained in 7TD1 cells where p23 induction occurs in the absence of apoptosis. Since p23 results from the cleavage of p27 by a CPP32-like caspase our results support the hypothesis already suggested by others (Miossec et al., 1997; Singer et al., 1995; Wright et al., 1997) that caspases can be activated in the course of physiological functions unrelated to apoptosis. The fact that the cleavage of p27 occurred speci®cally in G 1 phase suggests that these proteases could be regulated during the progression through the cycle. In summary, we demonstrate that p23 is a potent cell growth inhibitor and that its induction does not hallmark a terminal event leading to apoptosis.
Further analysis of transfected cells indicate that ectopic 23 kDa protein exhibits similar localization and binding properties to that of endogenous p23 induced in 7TD1 cells. Indeed, p23, is present exclusively in the cytoplasm and binds to cyclin/CDK2 and cyclin/CDK4 with the same eciency as p27. Moreover we demonstrate that p23 was fully functional since it totally inhibits the activity of cyclin/CDK2 not only in vitro but also in intact cells. This observation is in total agreement with previous reports showing that the amino terminus of p27 is sucient to bind and to inhibit the cyclin/CDK2 complexes (Luo et al., 1995) . In contrast, our data dier from Levkau's study (Levkau et al., 1998) showing that the cleavage of p21 and p27 by a CPP32-like caspase leads to their dissociation from cyclin/CDK2 complexes and to the activation of cyclin A/CDK2. Furthermore, we found that p23 was ®ve to ten times more ecient than p27 in inhibiting CDK2 activity. These data suggest that the C-terminal part of p27 exerts a negative eect on its inhibitory activity, but further experiments are needed to elucidate the mechanisms underlying this phenomenon. Nevertheless, this hypothesis is consistent with the results of U È ren et al. (1997) which have shown that N-terminal and C-terminal domains of p27 can be endowed of opposite eects. Recent works (Morisaki et al., 1997; Shea et al., 1997; Vlach et al., 1997) have demonstrated that the phosphorylation of the Threonine 187 by cyclin E/CDK2 triggers the degradation of p27 following the ubiquitin/proteasome pathway. Mutagenesis experiments have shown that the mutation of this residue into Alanine or Valine prevents p27 degradation. According to our experiments, we can thus assume that the removal of Thr 187 consecutive to the cleavage of p27 at the caspase consensus site might also expend its biological half-life. Taken together, all these data suggest that, in vivo, the cleavage of p27 could be a relevant physiological mechanism to increase the activity and the stability of p27 and thus to control its biological activity without modi®cation of its expression level. This could be an appropriate mechanism to control cell proliferation, notably in hematopoietic cell lines like 7TD1 or U266 cells, in which p27 is highly expressed and weakly regulated during the cell cycle. Consequently, one can assume that, while p23 represents only 20% of the total p27/ p23 in DMSO-treated 7TD1 cells, it probably exerts a potent inhibitory action and likely participate to the cell cycle inhibition.
The abundance of p27 is thought to be regulated by translational and post-translational pathways, and less commonly at the level of transcription (Agrawal et al., 1996; Hengst and Reed, 1996; Roberts et al., 1994; Vlach et al., 1997) . Our own observation suggests that the in vivo proteolysis of p27 by a CPP32-like caspase during early G 1 arrest could be an additional posttranslational regulation pathway of p27. Indeed, we show that this cleavage lead to the generation of a 23 kDa protein that is a potent inhibitor of the cell cycle and plays an active role in G 1 growth arrest.
Materials and methods

Reagents
Recombinant human interleukin-6 (IL-6) (Proudfoot et al., 1993) was generously provided by Glaxo Institute for Molecular Biology (Geneva, Switzerland). Culture medium was from Life Technologies, Inc (Cergy Pontoise, France). Dimethyl sulfoxide (DMSO), nocodazole, aphidicolin, 8Br-cAMP, anisomycin and fetal calf serum used in 7TD1 and U266 cell cultures were from Sigma. SaOS-2 were grown in fetal calf serum purchased from GIBCO/BRL. Carbobenzoxy-Val-Ala-Asp-¯uoromethyl ketone (z-VAD-fmk) and acetyl-Asp-glu-Val-Asp-aldehyde (ac-DEVD-CHO) were from Alexis Biochemicals. Horseradish peroxidase conjugated rabbit anti-mouse, rabbit anti-goat and goat anti-rabbit were from DAKO (Denmark). Enhanced chemiluminescence (ECL) Western blotting kit reagents were from Amersham (Les Ulis, France). FuGENE 6 Transfection Reagent was purchased from Roche/Boehringer Mannheim.
Cell culture and cell cycle arrest experiments
7TD1 and U266 cells were cultured as previously described (Rezzonico et al., 1995) . Before each experiment, cells were harvested, sedimented by centrifugation and resuspended at 5610 5 cells/ml in fresh medium. In cell cycle arrest experiments, DMSO was added at 1.5%, aphidicolin at 1 mg/ml, nocodazole at 75 ng/ml and 8Br-cAMP at 500 mM for 24 h. To test the eect of caspase inhibitors, the cells were pretreated with or without ac-DEVD-CHO (100 mM) or z-VAD-fmk (50 mM) for 24 h before the addition of DMSO. SaOS-2 cells were cultured in RPMI 1640 supplemented with 10% fetal calf serum and in presence of antibiotics.
Cloning of p23 and p27
Human p27 and p23 cDNAs were generated by reverse transcription of 7TD1 total RNAs followed by PCR reactions using two sets of primers that were respectively: forward p27 and p23: 5'-GGAATTCGTCGACATGT-CAAACGTGCGAGTGTC-3'; reverse p27: 5'-ATAA-GAATGCGGCCGCTTACGTTTGACGTCTTCTGAGGC-3'; reverse p23: 5'-ATAAGAATGCGGCCGCAGTCTTTG-GGTCCACCAAATGCGTG-3'.
The EcoRI-NotI fragments of 591 bp (full-length p27) and 417 bp (p23) obtained by PCR were subcloned into pCDNA3 (clonTech) yielding constructs (named respectively pCDNAp27 and pCDNA-p23) that encodes for two proteins migrating with apparent molecular weights of 27 kDa (p27) and 23 kDa (p23).
P27 and p23 transfections experiments and cell cycle analysis
Growing SaOS-2 cells were plated at 0.4610 6 in 100 mm dishes, cultured overnight and transfected with 7 mg/dish of pCDNA3 alone, pCDNA3-p23 or pCDNA-p27 using the FuGENE 6 transfection reagent. After 36 ± 48 h in culture the cells were harvested and used in the described experiments. Cotransfection experiments were carried out using 0.5 mg/ml of pRcCMV containing either human CD4 or green¯uorescent protein (GFP) cDNA and 7 mg/ml of pCDNA3 alone, pCDNA-p23 or pCDNA-p27. CD4 immunostained cells were analysed by¯ow cytometry using a FACScan apparatus (Beckton Dickinson). Cell cycle analysis was performed by quantifying the DNA content using propidium iodide according to Vindelùv et al. (1983) . Apoptosis was estimated by double-labelling using annexin-5 and a mitochondrial potential probe (Castedo et al. 1996) .
Antibodies
The rabbit anti-p27 antibodies, p27(N90) directed against the amino acids 1 ± 90 of p27 was produced in our laboratory and immunopuri®ed as described previously (Ponzio et al., 1998) . Rabbit polyclonal antibodies to CDK4 (C-22), CDK2 (M2), N-terminal (N20) or C-terminal (C19) part of p27 and the polyclonal goat anti-human PARP antibody, were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Polyclonal rabbit anti-mouse p21 antibody was obtained from Pharmingen (San Diego, CA, USA). Monoclonal mouse anti-human caspase-3 (CPP32) was from Transduction Laboratory (USA). Polyclonal rabbit antimouse poly(ADP-ribose) polymerase (PARP) was from Roche/Boehringer Mannheim (France). Anti-CD4 antibody coupled to magnetic beads were from DYNAL (Dynabeads M-280).
Immunoblotting
Immunoblotting experiments were carried out as described previously (Ponzio et al., 1998) . Puri®ed anti-p27 polyclonal antibodies (N90), (N20) and (C19) were used at the concentration of 1, 0.2 and 0.5 mg/ml respectively. Anti-p21 antiserum was used at 1/1000 dilution. Anti-human PARP, anti-human CPP32 and anti-mouse PARP were used at 1/ 3000, 1/3000 and 1/6000 dilution respectively. Proteins were revealed using the Amersham ECL detection system, according to the manufacturer's protocol.
Immunoprecipitation
Cellular extracts (0.5 ± 2 mg of protein) prepared as described previously (Ponzio et al., 1998) were incubated for 2 h at 48C with anti-CDK2 (3 mg) or anti-CDK4 (3 mg) antibodies and then with protein A-sepharose beads for 1 h. Immunocomplexes were collected and analysed by Western blotting as described above.
In vitro and in vivo CDK2 kinase assay
To test the eect of p23 on CDK2 activity in vitro, SaOS-2 cells extracts containing identical amounts of recombinant p27 or p23 were incubated for 30 min at 378C with CDK2 immunoprecipitated from lysates of 7TD1 cells. The pellets were washed with Tris/HCl 20 mM pH 7.8, MgCl 2 4 mM, and the Histone H1 activity of these complexes was assayed as described by Dulic et al. (1992) . To determine the activity of CDK2 in p27 and p23-transfected cells, the positive CD4 + / pCDNA, CD4 + /p27 + and CD4 + /p23 + cells were puri®ed by anti-CD4 antibody coupled to magnetic beads. The beads were washed four times with PBS and the CD4 + positive cells (2610 6 cells) were lysed as described previously (Dulic et al., 1992) in RIPA buer. Cyclin/CDK2 complexes were immunoprecipitated using speci®c anti-CDK2 antibodies and their activity was measured using Histone H1 as substrate.
Gel ®ltration chromatography
Cells (10 8 ) incubated for 24 h with DMSO, were washed twice in PBS and lysed at 48C by sonication in hypotonic buer (HEPES 30 mM, NaCl 30 mM, pH 7.6) containing protease and phosphatase inhibitors. After ultracentrifuga-tion (100 000 g at 48C), supernatant (10 mg of protein) was applied onto Ultrogel AcA44 column (Sepracor) (40 62.5 cm) connected to FPLC system (BIORAD). Fractions (1.5 ml) were collected and 80 ml aliquots were assayed for p27, p23, CDK2 and CDK4 expression by Western blotting.
Abbreviations Ac-DEVD-CHO: Acetyl-Asp-Glu-Val-Asp-aldehyde; CDK: cyclin-dependent kinase; CKI: cyclin-dependent kinase inhibitor; DMSO: dimethylsulfoxide; PARP: Poly(ADP-ribose) polymerase; pRb: retinoblastoma protein; z-VAD-fmk: carbobenzoxy-Val-Ala-Asp-¯uoremethyl ketone; GFP: green¯uorescent protein.
